By Dr Benjamin Daniels

Journal articles

Tan SYS; O’Neill S; Goldstein D; Ward RL; Daniels B; Vajdic CM, 2018, 'Predictors of care for patients with cancer of unknown primary site in three Australian hospitals', Asia Pacific Journal of Clinical Oncology, 14, pp. e512 - e520, http://dx.doi.org/10.1111/ajco.12815

Lopez D; Daniels B; Sanfilippo F; Pearson S; Martini A; Preen DB, 2018, 'Needs and priority areas for building capacity for working with linked data in the Australian pharmacoepidemiology workforce', International Journal of Population Data Science, 3, http://dx.doi.org/10.23889/ijpds.v3i4.733

Daniels B; Kiely BE; Lord SJ; Houssami N; Lu CY; Ward RL; Pearson SA, 2018, 'Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016)', Breast Cancer Research and Treatment, 171, pp. 151 - 159, http://dx.doi.org/10.1007/s10549-018-4804-0

Daniels B; Girosi F; Tervonen H; Kiely BE; Lord SJ; Houssami N; Pearson SA, 2018, 'Adherence to prescribing restrictions for her2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016)', Plos One, 13, http://dx.doi.org/10.1371/journal.pone.0198152

Daniels B; Kiely BE; Lord SJ; Houssami N; Lu CY; Ward RL; Pearson SA, 2018, 'Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001–2016)', Breast, 38, pp. 7 - 13, http://dx.doi.org/10.1016/j.breast.2017.11.007

Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE, 2018, 'ROR1 and ROR2 play distinct and opposing roles in endometrial cancer', Gynecologic Oncology, 148, pp. 576 - 584, http://dx.doi.org/10.1016/j.ygyno.2018.01.025

Daniels B; Kiely BE; Houssami N; Lord SJ; Dobbins T; Lu CY; Ward RL; Pearson SA, 2018, 'Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: A national population-based observational study (2006-2014)', British Journal of Cancer, 118, pp. 441 - 447, http://dx.doi.org/10.1038/bjc.2017.405

Harris CA; Daniels BJ; Ward RL; Pearson SA, 2017, 'Retrospective comparison of Australia’s Pharmaceutical Benefits Scheme claims data with prescription data in HER2 positive early breast cancer patients (2008-2012)', Public Health Research and Practice, 27, http://dx.doi.org/10.17061/phrp2751744

Brett J; Daniels B; Karanges EA; Buckley NA; Schneider C; Nassir A; McLachlan AJ; Pearson SA, 2017, 'Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study', British Journal of Clinical Pharmacology, 83, pp. 2581 - 2588, http://dx.doi.org/10.1111/bcp.13369

Brett J; Karanges EA; Daniels B; Buckley NA; Schneider C; Nassir A; Zoega H; McLachlan AJ; Pearson SA, 2017, 'Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure', Australian and New Zealand Journal of Psychiatry, 51, pp. 990 - 999, http://dx.doi.org/10.1177/0004867417721018

Daniels B; Lord SJ; Kiely BE; Houssami N; Haywood P; Lu CY; Ward RL; Pearson SA, 2017, 'Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: Protocol detailing observations in a whole of population cohort', BMJ Open, 7, http://dx.doi.org/10.1136/bmjopen-2016-014439

Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2017, 'Validation of specificity of antibodies for immunohistochemistry: the case of ROR2', Virchows Archiv an International Journal of Pathology, 470, pp. 99 - 108, http://dx.doi.org/10.1007/s00428-016-2019-5

Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2016, 'Erratum to: Validation of specificity of antibodies for immunohistochemistry: the case of ROR2 (Virchows Archiv, (2016), 10.1007/s00428-016-2019-5)', Virchows Archiv, 469, pp. 717, http://dx.doi.org/10.1007/s00428-016-2036-4

Vajdic CM; Mayson E; Dodds AJ; O'Brien T; Wilcox L; Nivison-Smith I; Le Marsney R; Daniels B; Ashton LJ; Tan J; Bilmon I; Aarons D; Tran S; Gibson J; Johnston A; Greenwood M; Forbes M; Hertzberg M; Huang G; Spencer A; Muirhead J; Szer J; Mason K; Lewis I; To C; Durrant S; Western R; Cannell P; Buffery S; Oswald C; Nelson A; Shaw P; Pearson L; Tiedemann K; Scoyne M; Fraser C; Seljak J; Cole C; Rowland K; Gough H; Tapp H; Green N; Moa A; McRae J; Jenkins M; Hicks J; Chaplin K, 2016, 'Second Cancer Risk and Late Mortality in Adult Australians Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Population-Based Cohort Study', Biology of Blood and Marrow Transplantation, 22, pp. 949 - 956, http://dx.doi.org/10.1016/j.bbmt.2016.01.027

Cairns R; Daniels B; Wood DA; Brett J, 2016, 'ADHD medication overdose and misuse: The NSW poisons information centre experience, 2004-2014', Medical Journal of Australia, 204, pp. 154 - 154.e7, http://dx.doi.org/10.5694/mja15.00791

Cairns R; Daniels B; Wood DA; Brett J, 2016, 'ADHD medication overdose and misuse: the NSW Poisons Information Centre experience, 2004-2014', The Medical journal of Australia, 204, pp. 154

Mellish L; Karanges EA; Litchfield MJ; Schaffer AL; Blanch B; Daniels BJ; Segrave A; Pearson SA, 2015, 'The Australian Pharmaceutical Benefits Scheme data collection: A practical guide for researchers', BMC Research Notes, 8, pp. 634, http://dx.doi.org/10.1186/s13104-015-1616-8

Blanch B; Daniels B; Litchfield M; Pearson SA, 2015, 'Looking forward and looking back: The balancing act in new drug user designs for pharmacoepidemiological research', Pharmacoepidemiology and Drug Safety, 24, pp. 1117 - 1119, http://dx.doi.org/10.1002/pds.3848

Ward RL; Laaksonen MA; van Gool K; Pearson SA; Daniels B; Bastick P; Norman R; Hou C; Haywood P; Haas M, 2015, 'Cost of cancer care for patients undergoing chemotherapy: The elements of cancer care study', Asia Pacific Journal of Clinical Oncology, 11, pp. 178 - 186, http://dx.doi.org/10.1111/ajco.12354

Nelson AS; Ashton LJ; Vajdic CM; Le Marsney RE; Daniels B; Nivison-Smith I; Wilcox L; Dodds AJ; O'Brien TA; Moa A, 2015, 'Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy', Leukemia, 29, pp. 441 - 447, http://dx.doi.org/10.1038/leu.2014.203

Henry C; Quadir A; Hawkins NJ; Jary E; Llamosas E; Kumar D; Daniels B; Ward RL; Ford CE, 2015, 'Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling', Journal of Cancer Research and Clinical Oncology, 141, pp. 243 - 254, http://dx.doi.org/10.1007/s00432-014-1824-y

Bilmon IA; Ashton LJ; Le Marsney RE; Dodds AJ; O'brien TA; Wilcox L; Nivison-Smith I; Daniels B; Vajdic CM; Dodds A; Tan J; Aarons D; Tran S; Gibson J; Johnston A; Greenwood M; Forbes M; Hertzberg M; Huang G; Spencer A; Muirhead J; Szer J; Mason K; Lewis I; To C; Durrant S; Western R; Cannell P; Buffery S; Oswald C; Nelson A; Shaw P; Pearson L; Tiedemann K; Scoyne M; Fraser C; Seljak J; Cole C; Rowland K; Gough H; Tapp H; Green N; Moa A; McRae J; Jenkins M; Hicks J; Chaplin K, 2014, 'Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: A population-based cohort study', Bone Marrow Transplantation, 49, pp. 691 - 698, http://dx.doi.org/10.1038/bmt.2014.13

Couttas TA; Kain N; Daniels B; Lim XY; Shepherd C; Kril J; Pickford R; Li H; Garner B; Don AS, 2014, 'Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis', Acta Neuropathologica Communications, 2, http://dx.doi.org/10.1186/2051-5960-2-9

Abuhusain HJ; Matin A; Qiao Q; Shen H; Kain N; Day BW; Stringer BW; Daniels B; Laaksonen MA; Teo C; McDonald KL; Don AS, 2013, 'A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis', Journal of Biological Chemistry, 288, pp. 37355 - 37364, http://dx.doi.org/10.1074/jbc.M113.494740

Back to profile page